Antipsychotic Side Effects: EPS, Tardive Dyskinesia & Metabolic Monitoring

Antipsychotic side effects split along a predictable line: typical (first-generation) antipsychotics cause more extrapyramidal symptoms (EPS) from dopamine blockade, while atypical (second-generation) antipsychotics cause more metabolic side effects. Knowing the four EPS types, how to treat each, the metabolic monitoring schedule, prolactin effects, and clozapine's agranulocytosis risk will carry you through almost every antipsychotic question on the PMHNP-BC exam.

This review organizes the side effects so you can match the finding to the cause and the intervention. Clinical management requires current references — this is exam-focused study.

Typical vs. Atypical: The Core Trade-Off

• Typical (first-generation): Strong D2 dopamine blockade. High-potency agents (haloperidol, fluphenazine) cause more EPS and hyperprolactinemia; low-potency agents (chlorpromazine) cause more sedation and anticholinergic effects.
• Atypical (second-generation): Block D2 plus serotonin (5-HT2A), which lowers EPS risk but raises metabolic risk (weight gain, diabetes, dyslipidemia).

Pearl: When the vignette describes movement problems, think typical/high-potency. When it describes weight gain, high glucose, or high lipids, think atypical.

Extrapyramidal Symptoms (EPS)

EPS come from dopamine blockade in the nigrostriatal pathway. Learn them by time of onset — a classic exam organizer.

1. Acute Dystonia (hours to days)

Sudden, sustained muscle contractions — torticollis, oculogyric crisis (eyes rolled up), laryngospasm (a medical emergency). Most common in young men early in treatment.

Treatment: Anticholinergics — benztropine or diphenhydramine (IM/IV), fast-acting.

2. Akathisia (days to weeks)

Inner restlessness and an inability to sit still — pacing, fidgeting. Often mistaken for worsening psychosis or anxiety (a key board trap).

Treatment: Beta-blockers (propranolol), sometimes benzodiazepines; lower the dose.

3. Parkinsonism (weeks)

Bradykinesia, rigidity, resting tremor, masked facies, shuffling gait — drug-induced Parkinson's.

Treatment: Anticholinergics (benztropine), amantadine, or reduce the dose.

4. Tardive Dyskinesia (TD) (months to years)

Late-onset, often irreversible involuntary movements — lip smacking, tongue protrusion, chewing, facial grimacing, choreoathetoid movements. Risk rises with duration of exposure, older age, and high-potency typicals.

Treatment: Stop or switch the antipsychotic (often to an atypical like clozapine or quetiapine); VMAT2 inhibitors — valbenazine or deutetrabenazine. Anticholinergics do not help and can worsen TD — a high-yield distinction.

Mnemonic for EPS onset (hours to years): "4 hours, 4 days, 4 weeks, 4 months" — dystonia, akathisia, parkinsonism, tardive dyskinesia.

The AIMS Exam

The Abnormal Involuntary Movement Scale (AIMS) screens for tardive dyskinesia. Baseline before starting an antipsychotic, then every 6 months (some recommend every 12 months for lower-risk patients). Early detection allows a medication change before TD becomes permanent.

Metabolic Syndrome and Monitoring (Atypicals)

Atypicals — worst with olanzapine and clozapine, lowest with aripiprazole, ziprasidone, and lurasidone — cause:

• Weight gain
• Hyperglycemia / new-onset type 2 diabetes
• Dyslipidemia

This cluster is metabolic syndrome, a major long-term risk. Monitor:

• Weight/BMI: baseline, then monthly for 3 months, then quarterly.
• Waist circumference: baseline and annually.
• Fasting glucose (or A1c): baseline, 12 weeks, then annually.
• Fasting lipids: baseline, 12 weeks, then annually (or every 5 years if normal).
• Blood pressure: baseline, 12 weeks, then annually.

Hyperprolactinemia

Dopamine normally suppresses prolactin, so D2 blockade raises prolactin. Worst with risperidone and high-potency typicals. Symptoms:

• Women: galactorrhea, amenorrhea, irregular menses
• Men: gynecomastia, erectile dysfunction, decreased libido
• Both: decreased bone density over time

Pearl: Aripiprazole is a partial dopamine agonist and is prolactin-sparing — a good switch for prolactin problems.

Clozapine: The High-Risk Agent

Clozapine is uniquely effective for treatment-resistant schizophrenia and reduces suicidality, but it carries serious, testable risks:

• Agranulocytosis — potentially fatal drop in neutrophils. Mandatory ANC monitoring through a REMS program (weekly initially, then less often). Hold for low ANC.
• Myocarditis — monitor for chest pain, fever, tachycardia early in treatment.
• Seizures — dose-dependent.
• Severe constipation / ileus, sedation, hypersalivation, and significant metabolic effects.

Neuroleptic Malignant Syndrome (NMS)

Any antipsychotic can trigger NMS — fever, lead-pipe rigidity, autonomic instability, altered mental status, and elevated CK. It is slow in onset and life-threatening. Contrast it with serotonin syndrome in serotonin syndrome vs. NMS.

How This Fits the Bigger Picture

Antipsychotics are a major section of the psychopharmacology high-yield cheat sheet, and clozapine's agranulocytosis is a marquee entry in psych medication black box warnings. Mastering the EPS-vs-metabolic trade-off ties the whole class together.

Practice Until You Can't Miss

Antipsychotic questions reward fast matching: dystonia to benztropine, akathisia to propranolol, TD to a VMAT2 inhibitor, atypicals to metabolic labs, clozapine to ANC. The way to make those links automatic is repetition with clinician-verified questions and rationales. Drill the free PMHNP question bank or create a free account to track your antipsychotic accuracy and walk in ready.